Vernalis & Genentech Enter into Drug Discovery Collaboration

UK-based pharma firm Vernalis has signed a drug discovery collaboration with Genentech.

U.K. drug developer Vernalis plc has entered into a drug discovery collaboration with Genentech, a member of the Roche Group.  Genentech will utilise Vernalis' fragment and structure-based drug discovery platform against an undisclosed target.

Ian Garland, CEO of Vernalis, commented: "We are delighted that Genentech has selected Vernalis to work with it on this target. Their selection of Vernalis further endorses our market leading fragment and structure-based drug discovery platform and validates our strategy to substantially fund our research activities through collaborations. We look forward to building a close working relationship with Genentech and ultimately a successful collaboration."

James Sabry, Vice President of Genentech Partn